Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Pharmacokinetics of Emraclidine in Healthy Male Participants
NCT06301971Phase 1Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Mar 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of emraclidine in schizophrenia, sponsored by Cerevel Therapeutics. Primary endpoints: Area Under the Concentration Time Curve from Zero to Infinity, Area Under the Concentration Time Curve from Time 0 to Last Quantifiable Concentration and 20 more. Started Mar 2024; status: completed.
02
Drugs
emraclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06301971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06301971.